Get the Stockscreener App
1.1601
4.11%
-0.0599
Hcw Biologics Inc stock is traded at $1.1601, with a volume of 3.46M.
It is down -4.11% in the last 24 hours and down -4.11% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
See More
Previous Close:
$1.22
Open:
$1.11
24h Volume:
3.46M
Relative Volume:
0.18
Market Cap:
$8.31M
Revenue:
$6.59M
Net Income/Loss:
$-18.12M
P/E Ratio:
-0.1226
EPS:
-9.4605
Net Cash Flow:
$-11.45M
1W Performance:
-0.86%
1M Performance:
-4.11%
6M Performance:
-34.28%
1Y Performance:
-78.13%
1-Day Range:
$1.06
$1.22
1-Week Range:
$1.06
$1.40
52-Week Range:
$0.25
$7.35
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
1.16 | 8.74M | 6.59M | -18.12M | -11.45M | -9.4605 |
VRTX
Vertex Pharmaceuticals Inc
|
449.73 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.46 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.90 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.34 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.46 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hcw Biologics Inc Stock (HCWB) Latest News
HCW Biologics Inc. Files Form 8-K with SEC Detailing Company and Stock Information - Minichart
HCW Biologics (HCWB) AGM 2026 Summary - Quartr
Shareholders back HCW Biologics (NASDAQ: HCWB) 2026 board slate - Stock Titan
HCW Biologics takes back rights to commercial-ready reagents - MSN
HCW Biologics Inc Stock Short Interest Rises to 58.43% - Quiver Quantitative
HCWB Announces Selling Shareholder Plans for 5.69M Shares - GuruFocus
HCW Biologics Registers Resale of Up to 5.7 Million Shares - marketscreener.com
HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock - TradingView
HCW Biologics (HCWB) files S-1 for resale of 5.69M PIPE shares and warrants - Stock Titan
HCW Biologics Inc. (HCWB) Holds Steady as Shares Consolidate Between Key Support and ResistanceWeak Sell Signals - newsline.com
Nasdaq Deadline Looms for HCW Biologics as Stock Slips Toward $1 Mark - Bez Kabli
Clark Hill Advises HCW Biologics in $4.0 Million PIPE Offering | News & Events | Clark Hill PLC - Clark Hill
HCW Biologics Wins Nasdaq Extension to Avoid Delisting - The Globe and Mail
HCWB Stock Price, Quote & Chart | HCW BIOLOGICS INC (NASDAQ:HCWB) - ChartMill
HCW Biologics Inc. Files Form 8-K with SEC: Company Details, Stock Information, and Emerging Growth Status - Minichart
Nasdaq grants HCW Biologics extension to regain minimum bid compliance By Investing.com - Investing.com Canada
Nasdaq grants HCW Biologics extension to regain minimum bid compliance - Investing.com UK
HCW Biologics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
HCW Biologics (HCWB) granted Nasdaq extension to fix $1 bid price deficiency - Stock Titan
MSN Money - MSN
HCW Biologics, Inc. Financial Disclosures & SEC Filings - TradingView
Maxim Group Maintains HCW Biologics(HCWB.US) With Buy Rating, Raises Target Price to $5 - Moomoo
Maxim Group Maintains HCW Biologics(HCWB.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
HCWB Maintained by Maxim Group -- Price Target Raised to $5.00 - GuruFocus
Top insider buys and sells disclosed for Wednesday By Investing.com - Investing.com UK
HCW Biologics CFO Rebecca Byam buys $20,000 in common stock By Investing.com - Investing.com Canada
HCW Biologics CEO Wong buys $159,999 in common stock By Investing.com - Investing.com South Africa
HCW Biologics CEO Wong buys $159,999 in common stock - Investing.com
HCW Biologics CFO Rebecca Byam buys $20,000 in common stock - Investing.com
HCW Biologics director Scott T. Garrett purchases $250,000 in stock - Investing.com
HCW Biologics director Scott T. Garrett purchases $250,000 in stock By Investing.com - Investing.com Canada
HCW Biologics (HCWB) CEO boosts stake with stock and warrant buys - Stock Titan
HCW Biologics (HCWB) director adds common shares and long-dated warrants - Stock Titan
HCW Biologics CFO buys shares and warrants | HCWB Insider Trading - Stock Titan
HCWB Regains Ex Vivo Rights for Key Compounds - GuruFocus
HCW Biologics regains ex vivo rights to CAR-T therapy reagents - Investing.com UK
HCW Biologics regains ex vivo rights to CAR-T therapy reagents By Investing.com - Investing.com South Africa
HCW Biologics (NASDAQ: HCWB) ends Wugen license, keeps 2.2M shares - Stock Titan
HCW Biologics to regain full rights for two commercial-ready reagents from Wugen - marketscreener.com
HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen - TradingView
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen - GlobeNewswire
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):